Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Daily News

COVID-19: TCTMD’s Dispatch for February Week 4

Todd Neale

February 21, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

Shelley Wood

November 17, 2020

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Industry News

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

May 06, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

News Daily News

Drug for Rare Form of Cardiomyopathy Meets Primary Endpoint in Phase III Trial

Todd Neale

March 30, 2018

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

ATTRibute-CM Top-Line Results Favorable for Acoramidis

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

COVID-19: TCTMD’s Dispatch for February Week 4

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Drug for Rare Form of Cardiomyopathy Meets Primary Endpoint in Phase III Trial

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content